Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 353

1.

Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.

Lawton CAF, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Rabinovitch R, Roach M 3rd, Kwok Y, Dignam JJ, Sandler HM.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):296-303. doi: 10.1016/j.ijrobp.2017.02.004. Epub 2017 Feb 12.

2.

Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202.

Mirhadi AJ, Zhang Q, Hanks GE, Lepor H, Grignon DJ, Peters CA, Rosenthal SA, Zeitzer K, Radwan JS, Lawton C, Parliament MB, Reznik RS, Sandler HM.

Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):511-515. doi: 10.1016/j.ijrobp.2016.11.002. Epub 2016 Nov 8.

3.

A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02.

Pollack A, Dignam JJ, Diaz DA, Wu Q, Stoyanova R, Bae K, Dicker AP, Sandler H, Hanks GE, Feng FY.

Clin Cancer Res. 2014 Dec 15;20(24):6379-88. doi: 10.1158/1078-0432.CCR-14-0075. Epub 2014 Oct 7.

4.

Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer.

Pahlajani N, Ruth KJ, Buyyounouski MK, Chen DY, Horwitz EM, Hanks GE, Price RA, Pollack A.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1949-56. doi: 10.1016/j.ijrobp.2011.04.005. Epub 2011 Jul 15.

5.

Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials.

Hamstra DA, Bae K, Pilepich MV, Hanks GE, Grignon DJ, McGowan DG, Roach M, Lawton C, Lee RJ, Sandler H.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1293-301. doi: 10.1016/j.ijrobp.2010.07.2004. Epub 2011 Mar 31. Review.

6.

Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer.

Roach M 3rd, Bae K, Lawton C, Donnelly BJ, Grignon D, Hanks GE, Porter A, Lepor H, Venketesan V, Sandler H.

Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1314-22. doi: 10.1016/j.ijrobp.2009.09.073. Epub 2010 Apr 8.

7.

MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02.

Khor LY, Bae K, Paulus R, Al-Saleem T, Hammond ME, Grignon DJ, Che M, Venkatesan V, Byhardt RW, Rotman M, Hanks GE, Sandler HM, Pollack A.

J Clin Oncol. 2009 Jul 1;27(19):3177-84. doi: 10.1200/JCO.2008.19.8267. Epub 2009 May 26.

8.

Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial.

Ray ME, Bae K, Hussain MH, Hanks GE, Shipley WU, Sandler HM.

J Natl Cancer Inst. 2009 Feb 18;101(4):228-36. doi: 10.1093/jnci/djn489. Epub 2009 Feb 10.

9.

Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR.

J Clin Oncol. 2009 Jan 1;27(1):92-9. doi: 10.1200/JCO.2007.12.3752. Epub 2008 Dec 1.

10.

Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02.

Smith MR, Bae K, Efstathiou JA, Hanks GE, Pilepich MV, Sandler HM, Shipley WU.

J Clin Oncol. 2008 Sep 10;26(26):4333-9. doi: 10.1200/JCO.2008.16.5845.

11.

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.

Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU.

J Clin Oncol. 2008 May 20;26(15):2497-504. doi: 10.1200/JCO.2007.14.9021. Epub 2008 Apr 14.

PMID:
18413638
12.

Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR.

Eur Urol. 2008 Oct;54(4):816-23. doi: 10.1016/j.eururo.2008.01.021. Epub 2008 Jan 15.

PMID:
18243498
13.

Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31.

Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR.

Cancer. 2007 Dec 15;110(12):2691-9.

14.

COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial.

Khor LY, Bae K, Pollack A, Hammond ME, Grignon DJ, Venkatesan VM, Rosenthal SA, Ritter MA, Sandler HM, Hanks GE, Shipley WU, Dicker AP.

Lancet Oncol. 2007 Oct;8(10):912-20. Epub 2007 Sep 18.

15.

Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202.

Che M, DeSilvio M, Pollack A, Grignon DJ, Venkatesan VM, Hanks GE, Sandler HM; RTOG.

Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1117-23. Epub 2007 Aug 8.

16.

Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02.

Khor LY, Moughan J, Al-Saleem T, Hammond EH, Venkatesan V, Rosenthal SA, Ritter MA, Sandler HM, Hanks GE, Shipley WU, Pollack A.

Clin Cancer Res. 2007 Jun 15;13(12):3585-90.

17.

What dose of external-beam radiation is high enough for prostate cancer?

Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE, Pollack A.

Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):682-9. Epub 2007 Mar 29.

18.

Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.

Valicenti RK, DeSilvio M, Hanks GE, Porter A, Brereton H, Rosenthal SA, Shipley WU, Sandler HM; Radiation Therapy Oncology Group Protocol 92-02.

Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1064-71. Epub 2006 Sep 18.

PMID:
16979837
19.

Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis.

Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Hanks GE, Zietman AL.

J Urol. 2005 Mar;173(3):797-802.

PMID:
15711272
20.

Androgen suppression plus radiation therapy for prostate cancer.

Horwitz EM, Feigenberg SJ, Pollack A, Hanks GE, Uzzo RG.

JAMA. 2004 Nov 3;292(17):2084-5; author reply 2085. No abstract available.

PMID:
15523065
21.

Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer.

Zelefsky MJ, Moughan J, Owen J, Zietman AL, Roach M 3rd, Hanks GE.

Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1053-61.

PMID:
15234039
22.
23.

Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.

Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M 3rd, Shipley WU, Hanks GE, Sandler HM.

J Clin Oncol. 2004 Jun 1;22(11):2133-40.

PMID:
15169799
24.

Prostate cancer radiotherapy dose response: an update of the fox chase experience.

Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Uzzo RG, Hanks GE.

J Urol. 2004 Mar;171(3):1132-6.

PMID:
14767286
25.
26.

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU; Radiation Therapy Oncology Group.

J Clin Oncol. 2003 Nov 1;21(21):3972-8. Erratum in: J Clin Oncol. 2004 Jan 15;22(2):386.

PMID:
14581419
27.

Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy.

Pollack A, Hanlon AL, Movsas B, Hanks GE, Uzzo R, Horwitz EM.

Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):19-23.

PMID:
12909210
28.

Positive prostate biopsy laterality and implications for staging.

Buyyounouski MK, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE, Pollack A.

Urology. 2003 Aug;62(2):298-303.

PMID:
12893339
30.

Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.

Uzzo RG, Pinover WH, Horwitz EM, Parlanti A, Mazzoni S, Raysor S, Mirchandani I, Greenberg RE, Pollack A, Hanks GE, Watkins-Bruner D.

Urology. 2003 Apr;61(4):754-9.

PMID:
12670560
31.

Impact of target volume coverage with Radiation Therapy Oncology Group (RTOG) 98-05 guidelines for transrectal ultrasound guided permanent Iodine-125 prostate implants.

Horwitz EM, Mitra RK, Uzzo RG, Das IJ, Pinover WH, Hanlon AL, McNeeley SW, Hanks GE.

Radiother Oncol. 2003 Feb;66(2):173-9.

PMID:
12648789
32.
33.

Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement.

Chism DB, Horwitz EM, Hanlon AL, Pinover WH, Mitra RK, Hanks GE.

Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):71-7.

PMID:
12504038
34.

Characteristics and quality assurance of a dedicated open 0.23 T MRI for radiation therapy simulation.

Mah D, Steckner M, Palacio E, Mitra R, Richardson T, Hanks GE.

Med Phys. 2002 Nov;29(11):2541-7.

PMID:
12462720
35.

Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings.

Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Greenberg RE, Stobbe C, Hanks GE, Pollack A.

Urology. 2002 Oct;60(4):634-9.

PMID:
12385924
36.

Prostate-specific antigen as a marker of disease activity in prostate cancer.

Partin AW, Hanks GE, Klein EA, Moul JW, Nelson WG, Scher HI.

Oncology (Williston Park). 2002 Sep;16(9):1218-24; discussion 1224, 1227-8 passim. Review.

37.

Measurement of intrafractional prostate motion using magnetic resonance imaging.

Mah D, Freedman G, Milestone B, Hanlon A, Palacio E, Richardson T, Movsas B, Mitra R, Horwitz E, Hanks GE.

Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):568-75.

PMID:
12243837
38.

Dose response in prostate cancer with 8-12 years' follow-up.

Hanks GE, Hanlon AL, Epstein B, Horwitz EM.

Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):427-35.

PMID:
12243818
39.

Prostate-specific antigen as a marker of disease activity in prostate cancer.

Partin AW, Hanks GE, Klein EA, Moul JW, Nelson WG, Scher HI.

Oncology (Williston Park). 2002 Aug;16(8):1024-38, 1042; discussion 1042, 1047-8, 1051. Review.

40.

Patterns of Care Study quantitative evaluation of the quality of radiotherapy in Japan.

Tanisada K, Teshima T, Ohno Y, Inoue T, Abe M, Ikeda H, Owen JB, Hanks GE, Masuda K, Honke Y.

Cancer. 2002 Jul 1;95(1):164-71.

41.

MRI simulation: effect of gradient distortions on three-dimensional prostate cancer plans.

Mah D, Steckner M, Hanlon A, Freedman G, Milestone B, Mitra R, Shukla H, Movsas B, Horwitz E, Väisänen PP, Hanks GE.

Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):757-65.

PMID:
12062622
42.

Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer.

Hanlon AL, Diratzouian H, Hanks GE.

Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):297-303.

PMID:
12023133
43.

Advantages of using noncoplanar vs. axial beam arrangements when treating prostate cancer with intensity-modulated radiation therapy and the step-and-shoot delivery method.

Price RA, Hanks GE, McNeeley SW, Horwitz EM, Pinover WH.

Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):236-43.

PMID:
12007964
44.

Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control.

Kaminski JM, Hanlon AL, Horwitz EM, Pinover WH, Mitra RK, Hanks GE.

Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):888-92.

PMID:
11958880
45.

Decision-making strategies for patients with localized prostate cancer.

Diefenbach MA, Dorsey J, Uzzo RG, Hanks GE, Greenberg RE, Horwitz E, Newton F, Engstrom PF.

Semin Urol Oncol. 2002 Feb;20(1):55-62.

PMID:
11828358
46.

Plasma levels of IGF-1, IGF-2, and IGFBP-3 in white and African-American men at increased risk of prostate cancer.

Winter DL, Hanlon AL, Raysor SL, Watkins-Bruner D, Pinover WH, Hanks GE, Tricoli JV.

Urology. 2001 Oct;58(4):614-8.

PMID:
11597555
47.

Hypoxia in human prostate carcinoma: an Eppendorf PO2 study.

Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Pinover WH, Greenberg RE, Stobbe C, Hanks GE.

Am J Clin Oncol. 2001 Oct;24(5):458-61.

PMID:
11586096
49.

Psychological and screening profiles of first-degree relatives of prostate cancer patients.

Miller SM, Diefenbach MA, Kruus LK, Watkins-Bruner D, Hanks GE, Engstrom PF.

J Behav Med. 2001 Jun;24(3):247-58.

PMID:
11436545
50.

To move or not to move: measurements of prostate motion by urethrography using MRI.

Mah D, Freedman G, Movsas B, Hanlon A, Mitra R, Horwitz E, Pinover W, Iyer R, Hanks GE.

Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):947-51.

PMID:
11429222

Supplemental Content

Loading ...
Support Center